Moderna and Merck Put Cancer Vaccine on Filing Clock

Merck and Moderna said on August 19 that their personalized mRNA cancer therapy intismeran, combined with Keytruda, met two Phase 3 endpoints in patients with completely resected stage IIB to IV melanoma.

The result is not an approval. It is the first late-stage readout that gives the partners a regulatory filing path for the individualized neoantigen therapy. The companies said overall-survival data are still being followed.

What the trial showed

The Merck and Moderna release says the Phase 3 INTerpath-001 study met endpoints for recurrence-free survival and distant metastasis-free survival at a pre-specified interim analysis.

The comparison was intismeran plus Keytruda versus Keytruda alone as adjuvant therapy after complete surgical resection. Merck and Moderna said the safety profiles were consistent with earlier combination studies and that no new safety signals were observed.

The release does not give the hazard ratios, event counts or full subgroup data. Those details are supposed to come at an international medical meeting. Until then, the clean claim is narrower: the study met the two named endpoints, and the partners plan to share the data with regulators.

Why the filing clock matters

INTerpath-001 is listed in the ClinicalTrials.gov record as a randomized Phase 3 melanoma study testing whether intismeran with pembrolizumab is better than pembrolizumab alone at preventing cancer from returning.

That makes the regulatory question more specific than the market reaction. The next issue is whether regulators accept the endpoint package for a filing, what the detailed safety and efficacy data show, and whether overall survival later supports the same direction.

For Moderna, the readout also moves a pipeline program closer to the commercial question. The Moderna Q1 2026 10-Q says Merck exercised its option for intismeran in 2022, paid a $250 million option fee, and that the companies collaborate on development and potential commercialization.

What remains unknown

The most important missing data are still numerical. The companies have not yet published the size of the recurrence-free survival benefit, the distant-metastasis benefit, discontinuation details, or overall-survival results.

The filing path also matters for both sides of the collaboration. Moderna's stock page and Merck's stock page will now be judged less on the headline that a cancer vaccine worked and more on the detailed evidence package regulators and oncologists can inspect.

For now, the new fact is strong but bounded: intismeran plus Keytruda cleared two Phase 3 melanoma endpoints. The follow-up is whether the full data are strong enough to turn a personalized mRNA therapy into an approved adjuvant melanoma option.

This article is informational only and is not investment, legal, tax or accounting advice.